About Tumor necrosis factor ligand superfamily member 8
Tumor necrosis factor ligand superfamily member 8 (TNFSF8) is a protein
from Homo sapiens identified by UniProt accession
P32971, 234 residues long.
MolForge cross-references it against 0 known binders and
181 disease associations.
Target properties
| Protein name | Tumor necrosis factor ligand superfamily member 8 |
|---|
| UniProt accession | P32971 |
|---|
| Gene | TNFSF8 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 234 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (181)
Diseases linked to this target (Open Targets).
- eosinophil count · score 0.50
- leukocyte count · score 0.47
- eosinophil percentage of leukocytes · score 0.44
- inflammatory bowel disease · score 0.37
- Crohn's disease · score 0.34
- neutrophil percentage of granulocytes · score 0.32
- eosinophil percentage of granulocytes · score 0.32
- sum of eosinophil and basophil counts · score 0.30
- neutrophil percentage of leukocytes · score 0.28
- primary biliary cirrhosis · score 0.26
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P32971-F1 | alphafold | PREDICTED | 78.88 | — |
Amino-acid sequence (234 residues)
MDPGLQQALN GMAPPGDTAM HVPAGSVASH LGTTSRSYFY LTTATLALCL VFTVATIMVL VVQRTDSIPN SPDNVPLKGG NCSEDLLCIL KRAPFKKSWA YLQVAKHLNK TKLSWNKDGI LHGVRYQDGN LVIQFPGLYF IICQLQFLVQ CPNNSVDLKL ELLINKHIKK QALVTVCESG MQTKHVYQNL SQFLLDYLQV NTTISVNVDT FQYIDTSTFP LENVLSIFLY SNSD
Explore Tumor necrosis factor ligand superfamily member 8 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets